| Private Placement / Financing Transactions
Ensoma: The company raised $135 million of Series B venture funding in a deal led by 5AM Ventures and Arix Bioscience on May 16, 2023, putting the company’s pre-money valuation at $130 million. Alexandria Venture Investments, Takeda Ventures and 12 other investors also participated in the round. The company is an operator of a biotech business intended to develop genomic medicine, pioneering a next-generation in vivo approach for treatment.
Boundless Bio: The company raised $100 million of Series C venture funding in a deal led by Leaps by Bayer on May 16, 2023, putting the company’s pre-money valuation at $150 million. Alexandria Venture Investments, Vertex Ventures HC, Nextech Invest, ARCH Venture Partners, City Hill Ventures, GT Healthcare Capital Partners, Fidelity Management & Research, Piper Heartland, RA Capital Management, Redmile Group, Wellington Management, Surveyor Capital, Logos Capital, PFM Health Sciences and Sectoral Asset Management also participated in the round. The company is a developer of transformative cancer therapies for patients with previously intractable cancers.
Ray Therapeutics: The company raised $100 million of Series A venture funding in a deal led by Novo Holdings on May 16, 2023, putting the company’s pre-money valuation at $50 million. MRL Ventures Fund, Platanus, 4BIO Capital, Deerfield Management, and Norwest Venture Partners also participated in the round. The company is a developer of novel optogenetic gene therapies designed for patients with blinding diseases.
Nido Biosciences: The company raised $74.6 million through a combination of Debt, Series B and Series B-1 venture funding in a deal led by Bioluminescence Ventures on May 15, 2023, putting the company’s pre-money valuation at $100 million. The company is a developer of small molecule therapeutics designed to treat neurodegenerative diseases.
Myeloid Therapeutics: The company raised $73 million of venture funding in a deal led by Hatteras Venture Partners on May 18, 2023. Alexandria Venture Investments, 8VC, Moore Strategic Ventures, Newpath Partners, ARCH Venture Partners, and Raptor Group also participated in the round. The company is a developer of a cell therapy platform designed to reprogram innate immune cells for eradicating diseases.
Metaphore: The company raised $50 million of venture funding from Flagship Pioneering on May 16, 2023. The company is an operator of a biotechnology business with products intended to trigger a desired biological response through biomimicry.
Eureka Therapeutics: The company closed on $20 million of an undisclosed targeted amount of venture funding on May 16, 2023. The company is a developer of an antibody-drug discovery technology designed to offer therapeutic antibody treatments.
Cyted: The company raised GBP 13.4 million of venture funding in a deal led by BGF and Morningside Ventures on May 18, 2023. The company is a developer of a digital diagnostic infrastructure platform designed to detect the early stages of cancer.
Laguna Health: The company raised $15 million through a combination of Series A, Series A1, and Series A2 venture funding in a deal led by HC9 Ventures and SemperVirens Venture Capital on May 16, 2023, putting the company’s pre-money valuation at $30 million. The company is a provider of artificial intelligence (AI)-powered contextual care management services intended to scale personalized care, starting with hospital transitions.
MediView: The company raised $15 million of venture funding from Cleveland Clinic, GE Healthcare, and JobsOhio Growth Capital on May 17, 2023. LLC, KKVS Syndicate, Inside View, and Mayo Clinic Ventures also participated in the round. The company is a developer of extended reality surgical navigation technology intended to maximize the accuracy and efficacy of cancer therapies.
Arterica: The company raised $2.5 million of venture funding in the form of equity and options from undisclosed investors on May 17, 2023. The company is an operator of a biotechnology platform intended to develop an approach to the percutaneous closure of large-bore vascular access.
Siren Biotechnology: The company raised an undisclosed amount of venture funding in a deal led by Founders Fund and Lux Capital on May 17, 2023. Innovation Endeavors, ARTIS Ventures, Civilization Ventures, and Savantus Ventures also participated in the round. The company is an operator of a biotech business intended to provide a gene therapy platform for a variety of cancer treatments.
|
